FEDERAL COURT OF AUSTRALIA
Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd [2020] FCAFC 116
Appeal from: Mylan Health Pty Ltd (formerly BGP Products Pty Ltd) v Sun Pharma ANZ Pty Ltd (formerly Ranbaxy Australia Pty Ltd) [2019] FCA 28 File number: NSD 182 of 2019 Judges: MIDDLETON, JAGOT, YATES, BEACH AND MOSHINSKY JJ Date of judgment: 3 July 2020 Catchwords: PATENTS – infringement – Swiss type claims – whether mental element imported into claims – whether it is necessary to establish manufacturer’s intention to prove infringement – discussion of correct approach to determining infringement
PATENTS – validity – lack of novelty – prior publication of documents – correct test for determining lack of novelty – whether there can be anticipatory disclosure by prior publication of the invention based on a reasoned hypothesis
PATENTS – validity – lack of inventive step – where case presented on basis of common general knowledge and documentary disclosure – whether primary judge erred in finding lack of inventive step on basis of common general knowledge alone
PATENTS – validity – whether claims fairly based on the matter described in the specification – proper construction of the specification
Legislation: Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)
Patents Act 1990 (Cth) ss 7(1)(a), 7(1)(b), 7(2), 7(3), 13(1), 40(3), 117(1), 117(2)(b)
Therapeutic Goods Act 1989 (Cth) s 9D(2)
Patents Act 1977 (UK) ss 125(1), 125(3)
European Patent Convention 2000
Cases cited: Aktiebolaget Hässle v Alphapharm Pty Ltd [2002] HCA 59; 212 CLR 411
Aldi Foods Pty Ltd v Moroccanoil Israel Ltd [2018] FCAFC 93; 133 IPR 375
Apotex Pty Ltd v Sanofi-Aventis [2008] FCA 1194; 78 IPR 485
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50; 253 CLR 284
Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) [2016] FCA 1238; 122 IPR 17
AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99; 226 FCR 324
Branir Pty Ltd v Owston Nominees (No 2) Pty Ltd [2001] FCA 1833; 117 FCR 424
Bristol-Myers Squibb Company v FH Faulding & Company Limited [2000]FCA 316; 97 FCR 524
Bristol-Myers Squibb Co v FH Faulding & Co Ltd (1998) 41 IPR 467
Flour Oxidizing Company Ltd v Carr & Company Ltd (1908) 25 RPC 428
General Tire & Rubber Co Ltd v Firestone Tyre & Rubber Co Ltd [1972] RPC 457
Generic Health Pty Ltd v Bayer Pharma Aktiengesellschaft [2014] FCAFC 73; 222 FCR 336
Generic Health Pty Ltd v Bayer Pharma Aktiengesellschaft [2018] FCAFC 183; 267 FCR 428
Generics (UK) v Warner-Lambert Company LLC [2018] UKSC 56; [2018] RPC 21
Hill v Evans (1862) 31 LJ Ch 456; 4 De GF & J 288; 45 ER 1195
Hospira UK Ltd v Genentech Inc [2014] EWHC 1094 (Pat)
Hospira UK Limited v Genentech Inc [2015] EWHC 1796 (Pat); [2016] RPC 1
ICI Chemicals & Polymers Ltd v Lubrizol Corporation Inc [2000] FCA 1349; 106 FCR 214
Keep reading for free
Create a free CaseChat account to read Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2020] FCAFC 116
- Decision Date
CaseChat Overview and Summary
The legal issues addressed by the court included whether Swiss type claims in a patent required an intention to be proven for infringement, the correct test for determining lack of novelty, the approach to establishing a lack of inventive step, and the proper construction of the patent specification to determine if claims were fairly based on the matter described.
The court found that the primary judge correctly determined that claims 12 and 13 were not fairly based on the matter described in the specification. The court held that the correct approach to determining infringement did not require establishing the manufacturer’s intention, and that the test for lack of novelty should not be based solely on a reasoned hypothesis. Additionally, the court found that the primary judge did not err in finding a lack of inventive step based on common general knowledge and documentary disclosure. As a result, Mylan’s appeal and Sun Pharma’s notice of contention were dismissed, and Mylan was ordered to pay Sun Pharma’s costs.
The orders of the court were that Mylan’s appeal be dismissed, Sun Pharma’s notice of contention be dismissed, and Mylan pay Sun Pharma’s costs. These orders reflect the court’s findings on the validity and infringement of the patent claims in question.
Orders
Orders of the court
1. The appeal be dismissed.
2. The first respondent’s notice of contention be dismissed.
3. The appellants pay the first respondent’s costs.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi